+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Advanced Practice Provider (NP/PA) Oncology Fellowship

Memorial Sloan-Kettering Cancer Center

Length of Program and Work Hours

The program starts October 19, 2026 and ends on October 2, 2027.
- The Hospice and Palliative Care subspecialty track starts on June 29, 2026 and ends on July 3, 2027.
Fellows may be asked to work nights, weekends, and/or holidays.
Average work week is about 50 hours to include clinical learning and protected didactic learning time.

Application

You will be asked to rank your top three preferences for subspecialty tracks when applying.

Please submit all required documents in one PDF.

Curriculum vitae
A personal statement
Three letters of recommendation

Personal Statement

The personal statement offers you an opportunity to discuss the talents, experiences, and goals that qualify you as a unique APP Fellowship candidate. We are seeking evidence of your qualifications and aptitude as well as your ability to communicate clearly and professionally. Personal statements should be no more than 500 words, typed, and double spaced using 12-point Times New Roman or Arial font.

Letters of Recommendation

Letters of recommendation will be uploaded by the applicant directly as part of the job application in one PDF document as noted above, they do not need to be sent directly to MSK by the writer. Letters of recommendation should be one from each of the following sources:

Peer/Colleague
Current or prior work supervisor
Advanced Practice Clinical Instructor, Faculty, Program Director, or Preceptor

AI Based Application Success Predictor

1. Strong cancer-specific scientific relevance

The most competitive applications directly address:

cancer biology
tumor evolution
precision oncology
cancer genomics
immunotherapy
targeted therapeutics
biomarker discovery
metastasis
early detection
cancer data science

MSK’s research portfolio is entirely cancer-focused, so clear oncology relevance is essential.

2. Clear translational impact

MSK strongly favors research that can move discoveries toward patients through:

new therapeutics
diagnostics
biomarker development
clinical trial translation
precision medicine implementation
improved cancer outcomes

Projects bridging laboratory discovery with clinical application tend to be highly competitive.

3. Innovation and high-risk/high-reward science

Successful applications often include:

novel biological mechanisms
innovative therapeutic platforms
AI in oncology
computational oncology
first-in-class drug concepts
advanced cancer technologies

MSK’s Starr Foundation Program for Discovery Science specifically funds “ambitious, highly creative” science.

4. Strong preliminary or proof-of-concept data

Competitive proposals usually include:

pilot mechanistic findings
translational feasibility data
preclinical therapeutic evidence
biomarker validation
early clinical datasets

Strong preliminary evidence significantly improves reviewer confidence.

5. Rigorous methodology and feasibility

High-scoring proposals generally demonstrate:

robust experimental or clinical design
realistic milestones
validated methods
strong statistical planning
reproducibility
feasible execution plan

Weak feasibility is a common reviewer concern.

6. Strong multidisciplinary collaboration

MSK strongly supports collaborative science involving:

medical oncologists
surgeons
computational biologists
immunologists
pathologists
radiologists
geneticists
bioinformaticians

Cross-disciplinary team science is a recurring feature of highly funded MSK projects.

7. Alignment with institutional strategic priorities

Applications aligned with MSK’s strategic strengths tend to perform especially well, including:

immuno-oncology
leukemia research
rare cancers
computational oncology
cancer genetics
cell therapy
translational therapeutics
AI-driven cancer research

Recent MSK fundraising and research initiatives highlight AI, computational oncology, and drug resistance as key focus areas.

8. Strong investigator track record

Important predictors include:

impactful oncology publications
prior grant success
translational research productivity
independent scientific contribution
national or international recognition

For early-career awards, future leadership trajectory is especially important.

9. Potential to generate future external funding

MSK pilot and internal awards often prioritize projects likely to:

secure NIH/NCI funding
generate SPORE or program-project grants
attract philanthropic support
launch multicenter studies
produce high-impact publications

MSK has extensive infrastructure dedicated to helping investigators build toward larger external grants.

10. Strong training and mentorship environment

For fellowships or pilot awards, reviewers often assess:

quality of mentorship
access to institutional resources
training environment
career-development plan
collaboration network

MSK offers dedicated internal grant support and global cancer research training programs for developing investigators.

Common Reasons for Rejection

Frequent reviewer concerns include:

insufficient innovation
weak translational pathway
unclear cancer relevance
limited preliminary evidence
poor feasibility
weak collaborative structure
inadequate statistical rigor
unclear future funding trajectory

Specialties

Cancer

Oncology

Nursing

Others

Eligibility Requirements

You are a highly motivated critical thinker with a strong desire to care for the oncology patient population. You are empathetic, resourceful, you communicate well, and enjoy working interprofessionally. You are seeking a fellowship position in an environment that fosters mutual respect, leadership, ethical decision-making, critical thinking, and problem-solving.

All applicants must:

Have current New York State Registered Nurse (RN) and Nurse Practitioner (NP) licenses or a Physician Assistant (PA) license and appropriate NP/PA board certification as listed within each subspecialty description prior to the MSK credentialing deadline
Be graduates of an accredited Nursing, NP, and/or PA program in the United States

Eligible Countries:

United States

Sponsor Details

Sponsor Institute/Organizations: Memorial Sloan-Kettering Cancer Center

Sponsor Type: Corporate/Non-Profit

Address: 1275 York Avenue New York, NY 10065

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity